Respiratory Medicine
Volume 95, Issue 1 , Pages 83-89 , January 2001

Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the U.K.

  • D.B. PRICE

      Affiliations

    • University of Aberdeen, U.K.
    • ,
  • R.H. BEN-JOSEPH

      Affiliations

    • Merck & Co., Inc. Whitehouse Station, NJ, U.S.A.
    • ,
  • Q. ZHANG

      Affiliations

    • Merck & Co., Inc. Whitehouse Station, NJ, U.S.A.

Received 9 June 2000 ,Accepted 25 October 2000.

References 

    References
  1. Scheffer, A, L, Global strategy for asthma management and prevention NHLBI/WHO workshop report, Bethesda, MD, National Institutes of Health, 1995
  2. Teeling-Smith, G, Asthma, London, Office of Health Economics (UK), 1990
  3. Barnes PH, Jonsson B, Klim JB. The costs of asthma. Eur Respir J. 1996;9:636–642
  4. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma. Arch Intern Med. 1998;158:1213–1220
  5. Leff JA, Busse WW, Pearlman D. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med. 1998;339:147–152
  6. Laviolette M, Malmstrom K, Lu S. Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med. 1999;160:1–7
  7. Leff JA. Leukotriene modifiers as novel therapeutics in asthma. Clin Exp Allergy. 1998;28:147–153
  8. Lofdahl C, Reiss TF, Leff JA. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. Br Med J. 1999;319:87–90
  9. Reiss TF, White R, Noonan G, Korenblat P, Hess J, Shingo S. Montelukast (MK-0476), a CysLT1receptor antagonist, improves the signs and symptoms of asthma over one year of treatment. Eur Respir J. 1997;10:437s–438s
  10. Thompson SG, Barber JA. How should cost data in pragmatic randomized trials be analyzed. BMJ. 2000;320:1197–1200
  11. Villaran C, O'Neill SJ, Helbling A. Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. J Allergy Clin Immunol. 1999;104:547–553
  12. Ramage L, Lipworth BJ, Ingram CG, Cree IA, Dhillon DP. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med. 1995;88:363–368
  13. Knorr B, Noonan G, McBurney J, Shingo S, Nguyen HH, Reiss TF. Evaluation of the long-term effect of montelukast in adult (≥15 years) and pediatric (6- to 14- years) patients. Eur Respir J. 1999;14:290s
  14. Donahue JG, Weiss ST, Livingston JM, Goetsch MA, Greineder DK, Platt R. Inhaled steroids and the risk of hospitalization for asthma. JAMA. 1997;277:887–891
  15. Jones K. Impact of an interest in asthma on prescribing costs in general practice. Qual Health Care. 1992;1:110–113
  16. Mellis CM, Peat JK, Woolcock AJ. The cost of asthma; can it be reduced?. Pharmacoeconomics. 1993;3:205–219
  17. Rutten-van Molken M PMH, Van Doorslaer E KA, Jansen M CC, Kerstjens H AM, Rutten F FH. Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;151:975–982
  18. Balkrishnan R, Norwood GJ, Anderson A. Outcomes and cost benefits associated with the introduction of inhaled corticosteroid therapy in a medicaid population of asthmatic patients. Clin Ther. 1998;20:567–580
  19. Pethica BD, Penrose A, MacKenzie D, Hall J, Beasley R, Tilyard M. Comparison of potency of inhaled beclomethasone and budesonide in New Zealand: retrospective study of computerised general practice records. BMJ. 1998;317:986–990

PII: S0954-6111(00)91006-0

doi: 10.1053/rmed.2000.1006

Respiratory Medicine
Volume 95, Issue 1 , Pages 83-89 , January 2001

Article Tools